Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 496.78% and ...

The obesity treatment market is dominated by Eli Lilly and Novo Nordisk, making it challenging for Viking. Read why I ...

The monthslong battle over the future of the weight-loss drug industry is headed for a climax this week, when the Food and ...

Powerful weight-loss drugs are expanding use of US health care as patients starting prescriptions are diagnosed with ...

Health-care companies fell amid concerns about regulation from the Trump administration. A retreat for UnitedHealth Group continued after President-elect Donald Trump vowed to root "middle men" out of ...

Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...

President Joe Biden wants Medicare and Medicaid to cover weight loss drugs, a proposal that would expand access to the costly but life-changing medications for millions of people who struggle with ...

MSNBC and CNN Fight to Dig Out of a Postelection Ratings Hole Ratings for the No. 2 and No. 3 cable news networks have plummeted since Donald Trump's victory, while Fox News remains the leader. ABC ...

The biotech's candidate VK2735 belongs to the same class of drugs as Eli Lilly's star weight loss drug Zepbound -- it acts on ...

The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...

The FDA is slated to reveal Thursday whether Eli Lilly’s supply of its obesity drug Zepbound can meet U.S. demand. The decision will have major implications both for Lilly and its competitor Novo ...

FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for ...